Business Description
Canbridge Pharmaceuticals Inc
ISIN : KYG1821D1097
Total Employee Number:
41Compare
Compare
Traded in other countries / regions
01228.Hong KongMF1.Germany IPO Date
2022-06-09Description
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.14 | |||||
Equity-to-Asset | -2.07 | |||||
Debt-to-Equity | -0.05 | |||||
Debt-to-EBITDA | 0.57 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -36.2 | |||||
Beneish M-Score | -1.01 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -16.3 | |||||
3-Year EPS without NRI Growth Rate | 45 | |||||
3-Year FCF Growth Rate | 51.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.9 | |||||
9-Day RSI | 47.97 | |||||
14-Day RSI | 47.45 | |||||
3-1 Month Momentum % | -1.52 | |||||
6-1 Month Momentum % | 3.17 | |||||
12-1 Month Momentum % | 219.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.24 | |||||
Quick Ratio | 0.2 | |||||
Cash Ratio | 0.15 | |||||
Days Inventory | 508.87 | |||||
Days Sales Outstanding | 93.85 | |||||
Days Payable | 10785.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.4 | |||||
Shareholder Yield % | 0.36 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.7 | |||||
Operating Margin % | -183.17 | |||||
Net Margin % | 28.53 | |||||
EBITDA Margin % | 57.26 | |||||
FCF Margin % | -76.54 | |||||
OCF Margin % | -76.53 | |||||
ROE % | Neg. Equity | |||||
ROA % | 11.13 | |||||
ROIC % | -78.21 | |||||
3-Year ROIIC % | -168.87 | |||||
ROC (Joel Greenblatt) % | 1035.88 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 66.13 | |||||
Price-to-Owner-Earnings | 16.14 | |||||
PS Ratio | 16.94 | |||||
EV-to-EBIT | 54.59 | |||||
EV-to-EBITDA | 31.44 | |||||
EV-to-Revenue | 18 | |||||
EV-to-FCF | -23.49 | |||||
Price-to-GF-Value | 5.73 | |||||
Earnings Yield (Greenblatt) % | 1.83 | |||||
FCF Yield % | -4.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Canbridge Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.049 | ||
| EPS (TTM) (€) | 0.004 | ||
| Beta | 2.655 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 1.77 | ||
| Volatility % | 270.43 | ||
| 14-Day RSI | 47.45 | ||
| 14-Day ATR (€) | 0.034898 | ||
| 20-Day SMA (€) | 0.17595 | ||
| 12-1 Month Momentum % | 219.67 | ||
| 52-Week Range (€) | 0.0635 - 0.306 | ||
| Shares Outstanding (Mil) | 511.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Canbridge Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Canbridge Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-31 | In 35 days | ||
| General meeting for 2025 | 2026-06-23 09:00 | 0.20 (+0.00%) | ||
| Annual report for 2025 | 2026-04-29 | 0.19 (-18.53%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 0.22 (-18.66%) | ||
| Second quarter earnings results for 2025 | 2025-08-31 | 0.19 (-21.07%) | ||
| General meeting for 2024 | 2025-06-27 09:00 | 0.02 (-10.91%) | ||
| Annual report for 2024 | 2025-04-30 | 0.01 (-6.90%) | ||
| Fourth quarter earnings results for 2024 | 2025-03-31 | 0.01 (-23.68%) | ||
| Second quarter earnings results for 2024 | 2024-08-29 | 0.03 (-3.45%) |
Show
Entries
Canbridge Pharmaceuticals Inc Frequently Asked Questions
What is Canbridge Pharmaceuticals Inc(FRA:MF1)'s stock price today?
The current price of FRA:MF1 is €0.17. The 52 week high of FRA:MF1 is €0.31 and 52 week low is €0.06.
When is next earnings date of Canbridge Pharmaceuticals Inc(FRA:MF1)?
The next earnings date of Canbridge Pharmaceuticals Inc(FRA:MF1) is 2026-08-31 Est..
Does Canbridge Pharmaceuticals Inc(FRA:MF1) pay dividends? If so, how much?
Canbridge Pharmaceuticals Inc(FRA:MF1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Canbridge Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers